Authors: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer and Courtney Granville, PhD, MSPH, Chief Scientific Officer, GO2 for Lung Cancer Earlier this year, GO2 for Lung Cancer welcomed Courtney Granville, PhD, MSPH, as [...]
Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer and Brittney Nichols, MPH, BSN-RN, Senior Specialist, Science and Research, GO2 for Lung Cancer Blood-based testing has become increasingly common in cancer care. In addition to routine [...]
Author: Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer Although most lung cancer cases happen at an older age and are associated with a history of smoking, a growing number of people are diagnosed who do [...]
Author: Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer Over the years, efforts to prevent lung cancer and teach the public about its link to smoking have resulted in negative and sometimes false viewpoints about the [...]
On May 16, 2024, the U.S. Food and Drug Administration (FDA) granted Imdelltra (tarlatamab-dlle) accelerated approval for people with extensive stage small cell lung cancer (ES-SCLC) following progression on or after platinum-based chemotherapy. The approval is based on results [...]
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer The first anti-cancer therapy, mechlorethamine, was approved in 1949. Since then, the U.S. Food and Drug Administration (FDA) has worked to ensure that new lifesaving [...]
Question: I have a family history of lung cancer – both my mother and grandmother were diagnosed with the disease. Am I at greater risk for lung cancer because of genetics? The role of genetics in determining someone’s [...]
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer On April 18, 2024, the U.S. Food and Drug Administration (FDA) approved Alecensa (alectinib) following surgical resection for people living with early-stage ALK-positive non-small cell lung [...]
Clinical Trial Aims to Unlock the Origins of Lung Cancer WASHINGTON and BOSTON, April 17, 2024 – In a promising step forward, GO2 for Lung Cancer (GO2), Dana-Farber Cancer Institute (Dana-Farber), and the Addario Lung Cancer Medical Institute (ALCMI), [...]
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer You’ve likely started to see artificial intelligence (AI) being used more and more in your everyday life. While the benefits and challenges of using AI [...]